<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34174504</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1950-6007</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>141</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</Title>
          <ISOAbbreviation>Biomed Pharmacother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Anti-cancer effects of Tranilast: An update.</ArticleTitle>
        <Pagination>
          <StartPage>111844</StartPage>
          <MedlinePgn>111844</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2021.111844</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0753-3322(21)00626-0</ELocationID>
        <Abstract>
          <AbstractText>Tranilast (TRN) or (N-3,4 -dimethoxy cinnamoyl]-anthranilic acid) is an analog of a tryptophan metabolite and is identified mainly as an anti-allergic agent with limited side effects. The anti-cancer effects of tranilast either alone or in combination with chemotherapeutic drugs have been evidenced in several pre-clinical studies. The main mechanism of action of tranilast includes targeting and modulation of various signaling and immune regulatory pathways including Transforming growth factor-beta (TGF-β), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), phosphatidylinositol 3-kinase (PI3K), MAP-Kinase (MAPK), Protein kinase B (‎Akt/PKB), c-Jun N-terminal kinase, modulation of cancer stem cells, etc. Most of these pathways are involved in tumor proliferation, invasion, and metastasis and it is postulated that tranilast, with its low toxicity profile and high anti-carcinogenic abilities, can serve as a potential anti-tumorigenic agent. The main aim of this review is to provide updated information on the anti-cancer effects of tranilast and its significance as a therapeutic agent.</AbstractText>
          <CopyrightInformation>Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Osman</LastName>
            <ForeName>Soha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar; Translational Cancer Research Facility and Clinical Trial Unit, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar. Electronic address: V-SDafaalla@hamad.qa.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raza</LastName>
            <ForeName>Afsheen</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar; Translational Cancer Research Facility and Clinical Trial Unit, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar. Electronic address: ARaza@hamad.qa.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Al-Zaidan</LastName>
            <ForeName>Lobna</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar; Translational Cancer Research Facility and Clinical Trial Unit, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar. Electronic address: LAlZaidan@hamad.qa.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Inchakalody</LastName>
            <ForeName>Varghese Philipose</ForeName>
            <Initials>VP</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar; Translational Cancer Research Facility and Clinical Trial Unit, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar. Electronic address: VInchakalody@hamad.qa.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Merhi</LastName>
            <ForeName>Maysaloun</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar; Translational Cancer Research Facility and Clinical Trial Unit, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar. Electronic address: MMerhi@hamad.qa.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prabhu</LastName>
            <ForeName>Kirti S</ForeName>
            <Initials>KS</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Research Institute, Hamad Medical Corporation, Doha, Qatar. Electronic address: KPrabhu@hamad.qa.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abdelaziz</LastName>
            <ForeName>Nouha</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological and Environmental Sciences, Qatar University, Doha, Qatar. Electronic address: nouhaabdelaziz@outlook.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hydrose</LastName>
            <ForeName>Shereena</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar; Translational Cancer Research Facility and Clinical Trial Unit, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar. Electronic address: SHydrose1@hamad.qa.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uddin</LastName>
            <ForeName>Shahab</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Research Institute and Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar. Electronic address: SKhan34@hamad.qa.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dermime</LastName>
            <ForeName>Said</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar; Translational Cancer Research Facility and Clinical Trial Unit, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar. Electronic address: Sdermime@hamad.qa.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Biomed Pharmacother</MedlineTA>
        <NlmUniqueID>8213295</NlmUniqueID>
        <ISSNLinking>0753-3322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D062367">ortho-Aminobenzoates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>HVF50SMY6E</RegistryNumber>
          <NameOfSubstance UI="C012293">tranilast</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000903" MajorTopicYN="N">Antibiotics, Antineoplastic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062367" MajorTopicYN="N">ortho-Aminobenzoates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anti-carcinogenic drug</Keyword>
        <Keyword MajorTopicYN="N">Anti-inflammatory drug</Keyword>
        <Keyword MajorTopicYN="N">Combination therapy</Keyword>
        <Keyword MajorTopicYN="N">Tranilast</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>26</Day>
          <Hour>20</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34174504</ArticleId>
        <ArticleId IdType="doi">10.1016/j.biopha.2021.111844</ArticleId>
        <ArticleId IdType="pii">S0753-3322(21)00626-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
